A Review of Components of CAR-T Cell and It's Protocols

1. CAR-T Cell
By Aliakbar Esfahani, Faculty of ParaMedical Scienses,Mashhad University of
Medical Sciences, Mashhad, Iran
In the name of God

2. Immunology :
 physiological Immune Response
 Pathological Immune Response

3. *Immunotherapy :
*Components :
 Stimulation
 Suppression

4. Types of immunotherapy :
1)anti-cancer vaccine 2)checkpoint inhibitors
3)immune toxins 4)CAR (after second relapse)

5. CAR :
 Artificial receptor

6. *CAR-T Cell :
 CD8+
 CD4+
 T-Reg (Autoimmune)

8. (for solid or liquid Tumor)

10. CD28:

11. CD27 (Activator Check Point):
 Ligand CD70

13. CD134 (Ox-40):
 IL, CD8+/CD4+, Anti-Apoptosis

16. CAR-T cell Therapy Steps :
1) Luekapheresis :

17. 2) mononuclear cell elutriation

18. 3) anti-CD3/CD28–coated paramagnetic
beads for activation of T cells
 Dynabeads

20. DC removing advantages :
 Direct targeting (non-escapable)
 Low-Expression

22. Table:

28. Medium: X-VIVO 15,OpTimizer
X-VIVO™ 15 is similar in composition to X-VIVO™ 10 and has been optimized for
the proliferation of Tumor Infiltrating Lymphocytes (TIL) under serum-free conditions.
Please see Supplemental Information for additional hematopoietic cell applications.

31. References :
Thanks For Your Attention !
Ahmadi, M., King, J., Xue, S., Voisine, C., Holler, A. & Wright, G. 2011.
CD3 limits the efficacy of TCR gene therapy in vivo. Blood 118(13): 3528-3537. Bollard, C., Rooney, C. & Heslop, H. 2012.
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology 9(9): 510-
519. Carey, L. 2011.
Directed therapy of subtypes of triple-negative breast cancer. The Oncologist 16: 71-78. Chmielewski, M., Hombach, A. &
Abken, H. 2013.
Antigenspecific T-cell activation independently of the MHC: Chimeric antigen receptor-redirected T cells. Front Immunology 4:
371. Cribbs, A., Kennedy, A., Gregory, B. & Brennan, F. 2013.
Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T-cells. BMC
Biotechnology 13: 98. De Saint Basile, G., Ménasché, G. & Fischer, A. 2010
. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nature Reviews in Immunology 10: 568-579.
Dieci, M., Griguolo, G., Miglietta, F. & Guarneri, V. 2016.
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? Cancer Treatment Reviews 46: 9-
19. Elsahwi, K.S. & Santin, A.D. 2011.
ERBB2 overexpression in uterine serous cancer: A molecular target for trastuzumab therapy. Obstetrics and Gynecology
International 2011: 128295.
Eroles, P., Bosch, A., Pérez-Fidalgo, J.A. & Lluch, A. 2012.